补体C5a在慢性糖尿病并发症进展中诱导间充质干细胞凋亡
研究探讨2型糖尿病患者循环中MSC样细胞是否减少及其机制。结果显示循环MSC样细胞显著减少且与并发症相关,糖尿病血清通过补体系统而非高糖损害MSC存活,C5a依赖的FADD上调和BAX/Bcl-2比值升高介导凋亡,阻断C5a/C5aR可抑制移植MSC凋亡。
要点
- 2型糖尿病患者循环MSC样细胞显著减少,且与并发症相关。
- 糖尿病血清通过补体系统而非高糖水平损害MSC增殖和存活。
- C5a依赖的FADD上调和BAX/Bcl-2比值升高介导MSC凋亡,阻断C5a/C5aR可抑制。
核心结论
- C5a依赖的凋亡性死亡可能参与2型糖尿病患者的MSC缺陷和并发症进展。
- 因此,抗补体治疗可能是糖尿病并发症的一种新型干预手段。
研究设计与样本
- 研究采用FACS评估外周血中MSC样细胞的丰度。
- 使用选定的糖尿病血清(DS)和非糖尿病血清(NDS)样本分别模拟糖尿病和非糖尿病微环境。
- 采用多种检测方法分析不同血清条件下MSC的增殖和存活。
- 使用瘦素受体突变(Lepr db/db)小鼠在体内研究糖尿病微环境中MSC的存活。
主要发现
- 数据显示循环MSC样细胞丰度显著降低,且与2型糖尿病患者的并发症相关。
- DS通过补体系统而非暴露于高糖水平强烈损害培养扩增MSC的增殖和存活。
- DS诱导的MSC凋亡至少部分由补体C5a依赖的FADD上调和BAX/Bcl-2比值升高介导,中和C5a或药理学或遗传学抑制MSC上的C5aR可显著抑制该凋亡。
- 阻断C5a/C5aR通路显著抑制Lepr db/db受体小鼠中移植MSC的凋亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Regeneration and repair mediated by mesenchymal stem cells (MSCs) are key self-protection mechanisms against diabetic complications, a reflection of diabetes-related cell/tissue damage and dysfunction. MSC abnormalities have been reported during the progression of diabetic complications, but little is known about whether a deficiency in these cells plays a role in the pathogenesis of this disease. In addition to MSC resident sites, peripheral circulation is a major source of MSCs that participate in the regeneration and repair of damaged tissue. Therefore, we investigated whether there is a deficiency of circulating MSC-like cells in people with diabetes and explored the underlying mechanisms. METHODS: The abundance of MSC-like cells in peripheral blood was evaluated by FACS. Selected diabetic and non-diabetic serum (DS and NDS, respectively) samples were used to mimic diabetic and non-diabetic microenvironments, respectively. The proliferation and survival of MSCs under different serum conditions were analysed using several detection methods. The survival of MSCs in diabetic microenvironments was also investigated in vivo using leptin receptor mutant (Lepr db/db ) mice. RESULTS: Our data showed a significant decrease in the abundance of circulating MSC-like cells, which was correlated with complications in individuals with type 2 diabetes. DS strongly impaired the proliferation and survival of culture-expanded MSCs through the complement system but not through exposure to high glucose levels. DS-induced MSC apoptosis was mediated, at least in part, by the complement C5a-dependent upregulation of Fas-associated protein with death domain (FADD) and the Bcl-2-associated X protein (BAX)/B cell lymphoma 2 (Bcl-2) ratio, which was significantly inhibited by neutralising C5a or by the pharmacological or genetic inhibition of the C5a receptor (C5aR) on MSCs. Moreover, blockade of the C5a/C5aR pathway significantly inhibited the apoptosis of transplanted MSCs in Lepr db/db recipient mice. CONCLUSIONS/INTERPRETATION: C5a-dependent apoptotic death is probably involved in MSC deficiency and in the progression of complications in individuals with type 2 diabetes. Therefore, anticomplement therapy may be a novel intervention for diabetic complications.
引用
- Zhu M, He X, Wang XH, et al. Complement C5a induces mesenchymal stem cell apoptosis during the progression of chronic diabetic complications. Diabetologia. 2017. PMID: 28577176. doi:10.1007/s00125-017-4316-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。